JGV Papers in Press. Published September 10, 2014 as doi:10.1099/vir.0.067660-0
1
Title: Paramyxovirus-based production of Rift Valley fever virus replicon
2
particles
3 4
Running title: NDV based production of RVFV replicons
5 6
Paul J. Wichgers Schreura,1, Nadia Oreshkovaa,c, Frank Hardersb, Alex Bossersb, Rob J.
7
M. Moormanna,c, Jeroen Kortekaasa
8 9
a)
Department of Virology, Central Veterinary Institute of Wageningen University and
10
Research Centre, Lelystad, The Netherlands.
11
b)
12
University and Research Centre, Lelystad, The Netherlands.
13
c)
14
Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
Department of Infection Biology, Central Veterinary Institute of Wageningen Department of Infectious Diseases and Immunology, Virology Division, Faculty of
15 16
1Correspondence:
17
[email protected] 18
Tel. +31 320 238423
19
Fax. +31 320 38153
20 21 22
Contents category: Animal viruses – Negative strand RNA
23
Word count summary: 188
24
Number of figures: 7
25
Number of tables: 1
Word count main text: 4559
26 27 28
Keywords:
Rift
Valley
fever
virus,
29
glycoproteins, pseudotyping, replicon
Newcastle
disease
virus,
paramyxovirus,
30
Summary
31
Replicon particle-based vaccines combine the efficacy of live-attenuated vaccines with
32
the safety of inactivated or subunit vaccines. Recently, we developed Rift Valley fever
33
virus (RVFV) replicon particles, also known as nonspreading RVFV (NSR) and
34
demonstrated that a single vaccination with these particles can confer sterile immunity
35
in target animals. NSR particles can be produced by transfection of replicon cells, which
36
stably maintain replicating RVFV S and L genome segments, with an expression
37
plasmid encoding the RVFV glycoproteins, Gn and Gc, normally encoded by the M-
38
genome segment. Here, we explored the possibility to produce NSR with the use of a
39
helper virus. We show that replicon cells infected with a Newcastle disease virus
40
expressing Gn and Gc (NDV-GnGc) are able to produce high levels of NSR particles. In
41
addition, using reverse-genetics and site-directed mutagenesis, we were able to create an
42
NDV-GnGc variant that lacks the NDV fusion protein and contains 2 amino acid
43
substitutions in respectively Gn and HN. The resulting virus uses a unique entry
44
pathway that facilitates the efficient production of NSR in a one-component system. The
45
novel system provides a promising alternative for transfection-based NSR production.
46
Introduction
47
RVFV causes recurrent outbreaks among ruminants and humans across the African
48
continent, several islands off the coast of southern Africa and the Arabian Peninsula.
49
The virus is mainly transmitted by Aedine and Culicine mosquito vectors. The tri-partite
50
viral genome consists of a small (S), medium (M) and large (L) RNA genome segment of
51
negative polarity (Elliott, 1990, 1997). The S segment encodes a nucleoprotein (N) and a
52
non-structural protein named NSs, which is the main virulence factor by acting as an
53
antagonist of host innate immune responses (Billecocq et al., 2004; Bouloy et al., 2001;
54
Ikegami et al., 2009a, b; Muller et al., 1995). The M segment encodes a glycoprotein
55
precursor (GPC) that is co-translationally cleaved into Gn and Gc (Kakach et al., 1988),
56
which are the two major structural glycoproteins involved in virus-cell attachment and
57
membrane fusion. The M segment additionally encodes a 78-kDa protein of unknown
58
function that is incorporated in virions in the mosquito vector (Weingartl et al., 2014)
59
and a non-structural protein (NSm) with anti-apoptotic properties (Terasaki et al., 2013;
60
Won et al., 2007). The L segment encodes an RNA-dependent RNA polymerase
61
responsible for transcription and replication.
62
Recently, we and others developed the first generation RVFV replicon particles,
63
also known as nonspreading RVFV (NSR) (Dodd et al., 2012; Kortekaas et al., 2011).
64
These particles are able to infect cells, followed by genome replication and protein
65
expression but, due to the absence of the genes encoding the structural glycoproteins Gn
66
and Gc, are incapable of forming progeny particles. Their inherent safety greatly
67
facilitates studies on RVFV entry and fusion [18, 19]. Remarkably, NSR induces a
68
protective immune response in mice and sheep after a single immunization (Kortekaas et
69
al., 2011; Kortekaas et al., 2012; Oreshkova et al., 2013). Very recently, we also showed
70
that NSR is a potent vaccine vector. A single intranasal or intramuscular immunization
71
of mice with NSR expressing the hemagglutinin protein of influenza, from the NSs
72
location of the S-segment, provided full protection against a lethal dose of influenza virus
73
(Oreshkova et al., 2014).
74
NSR is produced by transfection of baby hamster kidney (BHK) cells, that stably
75
maintain replicating L and S genome segments (replicon cells), with an expression
76
plasmid encoding RVFV Gn and Gc (Kortekaas et al., 2011). Although the transfection-
77
based production of NSR particles is relatively efficient, our laboratory is exploring
78
alternative systems for the cost-effective industrial-scale production of NSR vaccines
79
without the need for transfection or replicon cell lines. In this study, we evaluated
80
whether a paramyxovirus helper virus expressing the RVFV glycoproteins could be used
81
to produce NSR. The results show that a previously developed Newcastle disease virus
82
(NDV) expressing Gn and Gc (NDV-GnGc) is able to efficiently package RVFV L and S
83
genome segments into progeny NSR. Moreover, a NDV-GnGc mutant virus is described
84
that employs a unique entry mechanism, thereby enabling NSR production in a one-
85
component system.
86
Results
87
Production of NSR with NDV-GnGc
88
To evaluate whether RVFV L and S genome segments can be packaged by NDV
89
expressing Gn and Gc of RVFV, we infected BHK-Rep2 cells (Kortekaas et al., 2011) with
90
NDV-GnGc (Kortekaas et al., 2010). BHK-Rep2 cells are BHK-21 cells that constitutively
91
maintain replicating L and S genome segments of RVFV strain 35/74 (Kortekaas et al.,
92
2011). One day post infection supernatants were evaluated for the presence of progeny
93
NSR. As a positive control, BHK-Rep2 cells were transfected with pCAGGS-M, which is
94
known to facilitate NSR production (Kortekaas et al., 2011). Supernatants of both,
95
infected and transfected wells, contained up to 107 TCID50/ml of NSR progeny (Fig. 1).
96
Uninfected and non-transfected negative control cells did not produce any NSR progeny.
97
These results show that BHK cells maintaining replicating RVFV L and S genome
98
segments can efficiently be infected by NDV-GnGc and subsequently produce progeny
99
NSR.
100 101
Use of NDV-GnGc-∆F replicons to produce NSR
102
Although NDV-GnGc is a potent helper virus for the production of NSR, the production
103
of NDV-GnGc, due to the absence of a polybasic cleavage site in the F-protein, depends
104
on embryonated chicken eggs (Dortmans et al., 2011; Kortekaas et al., 2010). To
105
circumvent the use of embryonated chicken eggs for the production of NDV-GnGc and to
106
preserve optimal safety, we constructed an NDV-GnGc replicon virus that can efficiently
107
grow in cell culture. Using NDV reverse genetics (Peeters et al., 1999; Romer-Oberdorfer
108
et al., 1999), we deleted the entire F gene from NDV-GnGc thereby generating NDV-
109
GnGc-∆F (Fig. 2(a),(b),(d)). In addition, a QM5 cell line expressing the F protein of NDV
110
strain Herts/33 (de Leeuw et al., 2005) (QM5-FHerts) was constructed (Fig. 2(c)). The FHerts
111
fusion protein contains a polybasic cleavage site facilitating infection in various cell
112
types. As expected, NDV-GnGc-∆F was unable to grow on QM5 cells but able to grow on
113
QM5-FHerts cells, resulting in the formation of NDV specific syncytia (Fig. 2(e)). Titers of
114
NDV-GnGc-∆F reached up to 107 TCID50/ml. Infection of BHK-Rep2 cells, at different
115
multiplicities of infection (MOIs), with NDV-GnGc or NDV-GnGc-∆F showed that NDV-
116
GnGc-∆F is equally efficient in the production of progeny NSR as NDV-GnGc (Fig. 2(f)).
117 118
Stability of NDV-mediated NSR production
119
To investigate whether NDV-assisted NSR production can be stable over several cell
120
passages, we passaged BHK-rep2 cells infected with NDV-GnGc-∆F several times and
121
monitored virus titers in the culture media. In two independent experiments, a rapid
122
decrease in NSR titers in the supernatants of sequentially passaged cells was observed
123
(data not shown), whereas in one experiment, NSR titers detected in the supernatant of
124
passaged infected cells remained relatively stable over 3 cell passages (Fig. 3).
125
Remarkably, starting from cell passage 2, mild cytopathic effects (CPE) were noted. CPE
126
increased in time and after cell passage 3, all cells died. This suggested that NDV-GnGc-
127
∆F had gained the ability to spread to a certain extent.
128
To evaluate whether the supernatant of cell passage 3 contained infectious NDV-
129
GnGc-∆F, besides infectious NSR, we inoculated fresh BHK-21 cells with the collected
130
supernatant. The induction of CPE and the presence of NDV antigens in these cells
131
confirmed the presence of small amounts of infectious NDV-GnGc-∆F. Interestingly,
132
evaluation of supernatants of passage 4-7 revealed a remarkably stable ratio of NSR and
133
infectious NDV-GnGc-∆F particles of about 1000:1. Likely, limited amounts of infectious
134
NDV-GnGc-∆F are sufficient for high level NSR production. From here on the
135
combination of high-level infectious NSR particles and low-level infectious NDV-GnGc-
136
∆F particles is referred to as NSRNDV (Fig. 3).
137 138
Next-generation sequence analysis of NSRNDV
139
To evaluate possible nucleotide changes in the genomes of NDV-GnGc-∆F and NSR in
140
NSRNDV, resulting from a putative adaptation to the BHK cells, we sequenced the RNA
141
isolated from NSRNDV passage 7 (Fig. 3) using Illumina-based next-generation
142
sequencing. The analysis, with a minimal coverage of 200, revealed that none of the
143
genome segments of either NDV-GnGc-∆F or NSR contained insertions or deletions.
144
Moreover, there was no evidence of recombination events. Nevertheless, as shown in
145
Table 1, several single nucleotide polymorphisms (SNPs) were detected in both the NSR
146
and NDV-GnGc-∆F genome. NSR contained 6 SNPs and NDV-GnGc-∆F contained 4
147
SNPs present in ≥ 50% of sequence reads. The non-synonymous SNPs in NSR did not
148
give clues about the mechanism responsible for the changed phenotype. In contrast, the
149
non-synonymous SNPs detected in NDV-GnGc-∆F in the Gn (Y303S) and HN
150
(I192M) proteins could have effects on virus entry, fusion and subsequent spread.
151 152
Y303S in Gn and I192M in HN are responsible for in vitro spreading of
153
NDV-GnGc-∆F
154
To investigate a possible role of the amino acid substitutions in HN and Gn in the NDV-
155
GnGc-∆F genome in the in vitro spreading phenotype of NSRNDV, we decided to construct
156
single and double site-directed NDV-GnGc-∆F mutants (Fig. 4(a)). All NDV-GnGc-∆F
157
site-directed mutants were viable and able to grow efficiently in QM5-FHerts cells up to
158
titers of 10E7 TCID50/ml (Fig. 4(b)). Remarkably, NDV-GnGc-∆F-HN* and NDV-Gn*Gc-
159
∆F-HN* containing the I192M substitution in HN showed increased syncytia
160
formation in the QM5-FHerts cells (Fig. 4(c)).
161
Infection of BSR cells with the site-directed mutants, grown on QM5-FHerts cells,
162
showed a significant variation in plaque formation (Fig. 4(c)). NDV-GnGc-∆F
163
predominantly infected single cells, whereas NDV-Gn*Gc-∆F and NDV-Gn*Gc-∆F-HN*
164
containing the Y303S substitution in Gn were able to spread to neighbouring cells.
165
Interestingly, BSR cells infected with the double site-directed mutant NDV-Gn*Gc-∆F-
166
HN* showed large virus plaques. Passage of supernatants to fresh cells revealed that
167
NDV-Gn*Gc-∆F and NDV-Gn*Gc-∆F-HN* are able to produce limited amounts of
168
infectious progeny in BSR cells.
169
We subsequently investigated the feasibility of using the NDV-Gn*Gc-∆F and
170
NDV-Gn*Gc-∆F-HN* viruses to produce NSR. BHK-Rep2 cells were infected with the
171
different site-directed mutants (grown on QM5-FHerts cells) and the levels of NSR progeny
172
in the supernatants were determined. The results show that none of the mutations had a
173
significant effect on the transient NDV-GnGc-∆F-mediated production of NSR (Fig. 4(e,
174
first bars). However, passage of the supernatants of infected BHK-Rep2 cells to fresh
175
wild-type BHK cells resulted in a rapid decrease of NSR production when using NDV-
176
GnGc-∆F, NDV-Gn*Gc-∆F or NDV-GnGc-∆F-HN* (Fig. 4(e)). In contrast, incubation of
177
cells with passaged supernatant of NDV-Gn*Gc-∆F-HN*-infected BHK-Rep2 cells again
178
resulted in NSR progeny. Altogether, these results indicate that the autonomous
179
production of NSRNDV, as observed previously (Fig. 3), is mediated by two amino acid
180
substitutions in NDV-GnGc-∆F in respectively HN and Gn.
181 182
NSRNDV production in a one-component system
183
To investigate whether NSRNDV could be produced repeatedly, we passaged supernatants
184
of NDV-Gn*Gc-∆F-HN* based NSRNDV, in BSR cells. The titers of NSR and NDV-Gn*Gc-
185
∆F-HN* were determined by monitoring eGFP expression and CPE, respectively. Of
186
note, immunoperoxidase monolayer assays (IPMA) demonstrated that CPE correlated
187
with Gn expression from the NDV genome. When no complete CPE was observed after
188
initial infection, due to lower levels of infectious NDV-Gn*Gc-∆F-HN*, cells instead of
189
supernatants were passaged. Ratios between NSR and NDV in each passage of NSRNDV
190
varied between 1:100 to 1:1000 (Fig. 4(f)). Altogether, these results indicate that NSRNDV
191
production is relatively stable upon passage and can be produced in a one-component
192
system (Fig. S1).
193 194
Spread NDV-Gn*Gc-∆F-HN* is mediated by RVFV Gn and Gc
195
To investigate whether RVFV Gn and Gc are involved in the cell entry of NDV-Gn*Gc-
196
∆F-HN* we incubated the virus with serial dilutions of a RVFV neutralizing serum. As a
197
control, we evaluated neutralization of NDV-GnGc and NDV-GnGc-∆F. In these
198
experiments, infection by NDV-GnGc or NDV-GnGc-∆F was not neutralized, whereas
199
infection by NDV-Gn*Gc-∆F-HN* was completely prevented by serum diluted up to 540
200
times (Fig. 5). Altogether, these results strongly suggest that infectivity of NDV-Gn*Gc-
201
∆F-HN* depends on the RVFV glycoproteins.
202 203
NSRNDV induces a protective immune response in mice
204
To investigate whether NSRNDV is equally effective as an NSR vaccine produced by
205
transfection, we performed a vaccination challenge experiment in mice. Mice were either
206
vaccinated with NSR (105.8 TCID50), NSRNDV (containing 105.8 TCID50 NSR and 102.8
207
TCID50 NDV-GnGc-∆F) or NDV-GnGc-∆F (102.8 TCID50) and challenged 3 weeks post
208
vaccination. As expected, the low amount of NDV-GnGc-∆F alone was unable to provide
209
protection and the challenge virus disseminated in high amounts to the brain and liver
210
(Fig. 6). In contrast, NSR and NSRNDV-vaccinated mice were completely protected from a
211
lethal RVFV challenge dose without any virus disseminating to the organs. Protection
212
could be correlated to high levels of neutralizing antibodies, which were detected before
213
challenge infection (Fig. 6(b)). In conclusion, NSR produced by the NDV-Gn*Gc-∆F-HN*
214
helper virus is able to protect mice against a lethal challenge dose.
215
Discussion
216
In previous work, we demonstrated that nonspreading RVFV (NSR) is highly effective in
217
preventing viremia and clinical disease in the natural target species. Our laboratory is
218
currently developing NSR production systems that are cost-effective and scalable. Here,
219
we evaluated the feasibility to produce NSR using a Newcastle disease virus (NDV) to
220
provide the RVFV structural glycoproteins Gn and Gc.
221
NDV-GnGc is able to induce a neutralizing immune response in mice and sheep
222
(Kortekaas et al., 2010; Kortekaas et al., 2012), strongly suggesting that Gn and Gc,
223
when expressed from the NDV genome, are correctly processed and assembled. The
224
ability of NDV-GnGc to complement the RVFV glycoproteins in the BHK-Rep2 cells was
225
therefore
226
complementation is explained by a combination of factors: i) high level expression and
227
correct processing of GnGc from the NDV genome, ii) none or low-level of competition
228
between NSR and NDV genome replication, and iii) the ability of NDV and NSR to infect
229
the same cell. Likely the highly similar nature of the NSR and NDV genomes, both
230
negative-sense, single-strand RNA, does not result in unbalanced use of host cell
231
machinery. We expect that similar methods may be successful for production of other
232
bunyavirus replicons, although we envisage that efficiencies will vary between certain
233
combinations of helper and replicon virus.
not
totally
unexpected.
Overall,
the
success
of
the
NDV-based
234
NDV-GnGc is based on lentogenic NDV strain LaSota and requires trypsin-like
235
proteases for cleavage and subsequent activation of the F protein. Growth of lentogenic
236
NDV is therefore most efficient in the allantoic cavity of embryonated eggs, where
237
trypsin-like proteases are abundant (Goldhaft, 1980; Kortekaas et al., 2010). To
238
circumvent the need for embryonated eggs, mesogenic or velogenic NDV strains can be
239
used that contain a polybasic-cleavage site in the F protein and thereby do not require
240
trypsin-like proteases for infectivity. However, these viruses are not avirulent and are
241
therefore not suitable for vaccine applications. As a safe alternative, we constructed an
242
NDV-GnGc-∆F replicon which can be amplified in a QM5 cell line constitutively
243
expressing a fusogenic F protein. The ability to construct a cell line stably expressing
244
high levels of a fusogenic F protein (Fig. 2(c)) may be partly related to the absence of the
245
HN protein. Indeed, several reports show that F mainly induces syncytia and cell death
246
in the presence of HN (de Leeuw et al., 2005; McGinnes et al., 2002; Sergel et al., 2000).
247
Although to our knowledge this is the first report that describes the construction of an
248
NDV replicon, several replicons have been developed for other paramyxoviruses,
249
including the Respiratory syncytial virus (RSV) (Malykhina et al., 2011) and Sendai
250
virus (Yoshizaki et al., 2006). Likely, deleting and subsequently trans-complementing
251
glycoproteins can be generally applied for members of the Paramyxoviridae.
252
After observing that a mixture of NSR and NDV-GnGc-∆F virus (named NSRNDV),
253
contained low levels of autonomously replicating NDV, the genome sequences of the
254
respective viruses were determined by next-generation sequencing. This analysis
255
revealed the presence of several SNPs in both genomes. We decided to focus on the SNPs
256
of NDV-GnGc-∆F that were present in ≥ 95% of sequence reads and located in the
257
glycoprotein genes, since these proteins are involved in receptor binding and fusion. The
258
ag transition in HN, resulting in amino acid change I192M, was of particular
259
interest, because this mutation was previously described and characterized by Estevez et
260
al. (Estevez et al., 2011), who showed that the I192M substitution decreased
261
hemagglutinating activity and increased fusion activity. Our results are in full
262
agreement with these observations and emphasize that paramyxovirus fusion activity is
263
a dynamic process that can be influenced by subtle changes in the HN globular head
264
(Porotto et al., 2012). We hypothesize that the HN mutation increases the binding
265
capacity of the NDV virion to the cell surface due to prolonged receptor contact, although
266
this remains to be confirmed experimentally.
267
The SNP in Gn was not reported previously. The mutation does not significantly
268
affect the infectivity of NSR. Titers of NSR produced by NDV-Gn*Gc-∆F and NDV-
269
Gn*Gc-∆F-HN* were only slightly decreased compared to NSR titers produced by NDV-
270
GnGc-∆F. It is important to note that the Y303S substitution in Gn is required for the
271
F-independent infection of NDV-GnGc-∆F and that infectivity of NDV-Gn*Gc-∆F-HN*
272
can efficiently be blocked by RVFV-specific neutralizing antibodies. By combining these
273
two observations we hypothesise that Gn and Gc are incorporated in NDV-GnGc-∆F
274
virions as non-functional complexes that cannot mediate infectivity. However, our
275
findings suggest that a single substitution in the Gn protein (Y303S) results in a
276
functional GnGc complex that is capable to facilitate cell entry of NDV-GnGc-∆F virions
277
in the absence of F complementation. Whereas NDV normally uses a class-I fusion
278
protein (Chang & Dutch, 2012) to fuse at the plasma membrane, the ability of NDV-
279
Gn*Gc-∆F-HN* to autonomously replicate in tissue culture is apparently attributed to a
280
switch from a class I to a class II pH-dependent fusion protein-mediated entry (Fig. 7).
281
The mechanisms of entry of the NDV variants described in this study will be subject of
282
future research.
283
Wild-type RVFV induces strong CPE in various mammalian cell lines including
284
the BHK and BSR cell lines used in this study. Remarkably, BHK-Rep2 cells, which
285
stably maintain replicating RVFV L and S genome segments in the absence of a
286
replicating M-segment, do not show signs of CPE. Most likely, RVFV-mediated
287
cytotoxicity is caused by high-level expression of the M-segment encoded glycoproteins
288
Gn and Gc. In NSRNDV-infected cultures CPE was observed as well, although this CPE
289
was consistently less pronounced than CPE resulting from RVFV infection. Considering
290
that CPE resulting from incubation of cells with NSRNDV, is solely attributed to NDV-
291
Gn*Gc-∆F-HN*, CPE was used to determine titers of NDV-Gn*Gc-∆F-HN* virions in
292
NSRNDV preparations. Titers of NSR particles in NSRNDV preparations were determined
293
by detection of eGFP, expressed from the S-segment of the NSR genome. Remarkably,
294
multiple passage of NSRNDV revealed only minor variation in NSR progeny production
295
and ratio’s between NSR and NDV in NSRNDV preparations were relatively stable over
296
time.
297
To efficiently propagate NSRNDV in vitro, relatively high MOI infections are
298
required. Low MOI infections do not result in the production of progeny since this
299
depends on co-infection of a cell with NSR and NDV. In vivo administration of NSRNDV
300
will, due to the dilution effect, always result in low MOI infections and consequently
301
NSRNDV is unable to spread efficiently. This, together with the absence of the major
302
virulence factor NSs, highlights the safety of the NSRNDV vaccine.
303
In conclusion, we here show that NDV-GnGc and especially the variant referred
304
to as NDV-Gn*Gc-∆F-HN* can be used for efficient production of NSR. This novel system
305
could be further evaluated as a cost-effective alternative for transfection-based NSR
306
production.
307 308
Methods
309 310
Ethics statement
311
The animal experiment was conducted in accordance with the Dutch Law on Animal
312
Experiments (Wod, ID number BWBR0003081) and approved by the Animal Ethics
313
Committee of the Central Veterinary Institute (Permit Number: 2013050).
314 315
Cells and growth conditions
316
All cell lines were routinely maintained at 37°C and 5% CO2. BHK-21, BHK-Rep2 cells
317
and BSR cells were grown in Glasgow Minimum Essential Medium (GMEM; Invitrogen,
318
Bleiswijk, The Netherlands) supplemented with 4% tryptose phosphate broth (TPB;
319
Invitrogen), 1% non-essential amino acids (NEAA; Invitrogen), 5% fetal bovine serum
320
(FBS; Bodinco, Alkmaar, The Netherlands) and 1% penicillin-streptomycin (Invitrogen).
321
QM5 cells were routinely grown in QT35 medium (Invitrogen) supplemented with 5%
322
FBS and 1% penicillin-streptomycin. QM5-FHerts cells were grown in the same medium as
323
QM5 cells, supplemented with 0.5 mg/ml Geneticin (G-418; Promega, USA).
324 325
Viruses
326
RVFV strain 35/74 (Barnard, 1979) was grown and titrated on BHK cells. NDV-GnGc
327
(Kortekaas et al., 2010) was grown in embryonated chicken eggs and titrated on QM5
328
cells. Viral titers were determined by serial dilution and expressed as 50% tissue culture
329
infective dose (TCID50) using the Spearman-Kärber algorithm. In the absence of CPE or
330
eGFP expression, viral infection was visualized by IPMA (see below).
331 332
Construction of a QM5 cell line stably expressing the F protein of the NDV
333
Herts strain
334
QM5 cells were transfected with pCIneo-FHerts (de Leeuw et al., 2005) using jetPEI
335
transfection reagents (Polyplus-transfection SA, Illkirch, France) according to the
336
manufacturers’ instructions. Two days post transfection, G-418 selection reagent was
337
added to the growth medium at a concentration of 0.5 mg/ml. One week post selection,
338
individual clones (>50) were sub-cultured and finally screened for FHerts expression by
339
IPMA. The clone with the most stable and homogenous F expression after numerous
340
passages was used for further studies and is from here on referred to as QM5-FHerts.
341
342
NDV reverse-genetics
343
The rescue of NDV virus by reverse genetics was performed as described previously
344
(Peeters et al., 1999; Romer-Oberdorfer et al., 1999) with some minor modifications.
345
Briefly, 6 × 106 QM5-FHerts cells (per well of 6 wells plate) were infected with a Fowlpox
346
virus expressing T7 polymerase (FP-T7) (Chaudhry et al., 2007) in Opti-MEM containing
347
0.2% FBS (Invitrogen). Two hours post FP-T7 infection, medium was replaced (Opti-
348
MEM, 0.2% FBS) and cells were transfected with pCIneo-NP, pCIneo-P, pCIneo-L and a
349
plasmid encoding the complete cDNA of NDV strain LaSota (pNDFL) using jetPEI
350
transfection reagents according to manufacturers’ instructions. Three hours post
351
transfection medium was replaced with QT-35 medium containing 5% FBS and three
352
days post transfection supernatants were filtered (0.2 µM to remove FP-T7) and used to
353
inoculate fresh QM5-FHerts cells.
354 355
Construction of pNDFL-GnGc-∆F
356
To delete the F gene in the infectious clone of NDV-GnGc, a fusion PCR strategy was
357
conducted. Briefly, two PCR fragments were generated from pNDFL-GnGc (Kortekaas et
358
al., 2010) that flank the F-gene and contain about 20 nucleotides overlap using primer
359
pairs 1-2 and 3-4 (Table S1). The two purified fragments were subsequently used as
360
template in a fusion PCR reaction based on primers 1 and 4. The resulting fragment
361
was digested with HpaI and SpeI and ligated to pNDFL-GnGc digested with the same
362
enzymes. Plasmids were confirmed to have the expected sequences using Sanger
363
sequencing. The construct was designed to comply with the rule-of-6 (Peeters et al.,
364
2000).
365 366
IPMA
367
Immunoperoxidase monolayer assays (IPMAs) were performed as previously described
368
with some minor modifications (de Boer et al., 2010). Briefly, infected cell monolayers
369
were fixed with 4% (w/v) paraformaldehyde for 15 min, washed with PBS and
370
permeabilized with 1% Triton in PBS (5 min). After washing with washing buffer (PBS,
371
0.05% v/v Tween-20), cells were incubated for 30 min with blocking buffer (PBS, 5%
372
horse serum). Subsequently, primary antibody incubations were performed for 1 h at
373
37°C in blocking buffer. Expression of F protein was detected with monoclonal antibody
374
8E12A8C3 (de Leeuw et al., 2005), of Gn protein with monoclonal antibody 4-39-cc
375
(Keegan & Collett, 1986) and of Gc protein with a polyclonal rabbit antiserum against
376
the Gc ectodomain (de Boer et al., 2012). Secondary, HRP-conjugated antibody
377
incubations (DAKO) were also performed in blocking buffer for 1 h at 37°C. Between
378
incubations cells were washed 3 times with washing buffer. Antibody binding was
379
visualized using AEC substrate.
380 381
Next-generation sequencing
382
A volume of 6 ml cell culture supernatant of NSRNDV passage 7 was concentrated to 125
383
µl using an Amicon Ultra 30K centrifugal filter (Merck, Darmstadt, Germany).
384
Subsequently, 400 µl Trizol LS (Sigma-Aldrich, Missouri, United States) was added to
385
the concentrate and RNA was isolated using the Direct-zolTM RNA Miniprep kit (Zymo
386
research, California, United States) according the manufacturers’ instructions. Libraries
387
were prepared using the ScriptSeqTMv2 RNA-Seq Library Preparation kit (Epicentre
388
Biotechnologies, Wisconsin, United States). Quality and quantity of the library were
389
determined using the Bioanalyzer with the High Sensitivity DNA kit (Agilent
390
Technologies, California, United States) and the Qubit dsDNA HS Assay kit (Life
391
Technologies, New York, United States).
392
sequencing of the libraries was subsequently performed with an Illumina MiSeq V2
393
instrument. Raw sequencing data were trimmed and subjected to quality control using
394
in-house scripts. Virus-specific reads were mapped against the reference sequences using
395
Bowtie2 (Langmead & Salzberg, 2012) and local-sensitive mapped reads were visualized
396
using Tablet (Milne et al., 2013).
Cluster generation and paired-end 250 bp
397 398
Site-directed mutagenesis of NDV-GnGc-∆F
399
Site-directed mutants of NDV-GnGc-∆F were constructed using the Quickchange II XL
400
Site-Directed Mutagenesis kit (Agilent Technologies, Amstelveen, Netherlands) in
401
combination with standard cloning techniques using pNDFL-GnGc-∆F as a template.
402
Used primers (7-10) are listed in Table S1. Site-directed mutant infectious clones were
403
confirmed to have the expected sequence using Sanger sequencing.
404 405
In vitro neutralization of NDV-GnGc variants
406
Virus (MOI 0.05) was incubated with serial dilutions of a convalescent sheep serum
407
containing RVFV antibodies or a negative control serum for 1.5 h in complete GMEM
408
medium and subsequently added to 200.000 BHK cells per well of a 24 wells plate. Two
409
days post inoculation, infected cells were visualized using IPMA.
410 411
Vaccination and challenge of mice
412
Six-week-old female BALB/cAnCrl mice (Charles River Laboratories) were divided in 4
413
groups of 10 mice, kept in type III filter top cages under BSL-3 conditions, and allowed to
414
acclimatize for 6 days. At day 0, mice were vaccinated intramuscularly (thigh muscle)
415
with either medium (Mock), NSR-Gn (Oreshkova et al., 2013) (105.8 TCID50), NSRNDV
416
(NSR: 105.8 TCID50; NDV: 102.8 TCID50) or NDV-GnGc-∆F (102.8 TCID50) in 50 µl. Mice
417
were observed daily and three weeks post vaccination mice were challenged
418
intraperitoneally with 102.8 TCID50 of RVFV strain 35/74 in 0.1 ml medium. RVFV-
419
specific neutralization titers in sera were determined one day prior challenge, using a
420
previously developed RVFV neutralization assay (Kortekaas et al., 2011). Virus
421
dissemination to the livers was evaluated by qRT-PCR as described (Kortekaas et al.,
422
2012). Briefly, RNA was isolated of 200 µl 10% w/v organ suspension using the RNeasy
423
96 Kit (QIAGEN) according the manufacturers’ instructions. A volume of 5 µl purified
424
RNA was used as PCR template and RVFV specific RNA copy numbers in the 5 µl RNA
425
sample were determined using an in vitro synthesised RNA standard.
426
Acknowledgements
427
We like to thank Olav de Leeuw (CVI) for providing plasmids pCIneo-NP, pCIneo-P,
428
pCIneo-L and pCIneo-FHerts, Geoff Oldham (Institute for Animal Health, Compton,
429
United Kingdom) for providing FP-T7, Connie Schmaljohn (USAMRIID, Fort Detrick,
430
MD) for providing the Gn monoclonal antibody (4-39-cc) and Jet Kant (CVI) for technical
431
assistance. The project was performed within the Castellum program, which is
432
financially supported by the Dutch Ministry of Economic Affairs.
433
References
434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484
Barnard, B. J. (1979). Rift Valley fever vaccine--antibody and immune response in cattle to a live and an inactivated vaccine. Journal of the South African Veterinary Association 50, 155-157. Billecocq, A., Spiegel, M., Vialat, P., Kohl, A., Weber, F., Bouloy, M. & Haller, O. (2004). NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. Journal of virology 78, 9798-9806. Bouloy, M., Janzen, C., Vialat, P., Khun, H., Pavlovic, J., Huerre, M. & Haller, O. (2001). Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. Journal of virology 75, 1371-1377. Chang, A. & Dutch, R. E. (2012). Paramyxovirus fusion and entry: multiple paths to a common end. Viruses 4, 613-636. Chaudhry, Y., Skinner, M. A. & Goodfellow, I. G. (2007). Recovery of genetically defined murine norovirus in tissue culture by using a fowlpox virus expressing T7 RNA polymerase. The Journal of general virology 88, 2091-2100. de Boer, S. M., Kortekaas, J., Spel, L., Rottier, P. J., Moormann, R. J. & Bosch, B. J. (2012). Acid-activated structural reorganization of the rift valley Fever virus gc fusion protein. Journal of virology 86, 13642-13652. de Boer, S. M., Kortekaas, J., Antonis, A. F., Kant, J., van Oploo, J. L., Rottier, P. J., Moormann, R. J. & Bosch, B. J. (2010). Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 28, 2330-2339. de Leeuw, O. S., Koch, G., Hartog, L., Ravenshorst, N. & Peeters, B. P. (2005). Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein. The Journal of general virology 86, 17591769. Dodd, K. A., Bird, B. H., Metcalfe, M. G., Nichol, S. T. & Albarino, C. G. (2012). Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge. Journal of virology 86, 42044212. Dortmans, J. C., Koch, G., Rottier, P. J. & Peeters, B. P. (2011). Virulence of Newcastle disease virus: what is known so far? Veterinary research 42, 122. Elliott, R. M. (1990). Molecular biology of the Bunyaviridae. The Journal of general virology 71 ( Pt 3), 501-522. Elliott, R. M. (1997). Emerging viruses: the Bunyaviridae. Molecular medicine 3, 572577. Estevez, C., King, D. J., Luo, M. & Yu, Q. (2011). A single amino acid substitution in the haemagglutinin-neuraminidase protein of Newcastle disease virus results in increased fusion promotion and decreased neuraminidase activities without changes in virus pathotype. The Journal of general virology 92, 544-551. Goldhaft, T. M. (1980). Historical note on the origin of the LaSota strain of Newcastle disease virus. Avian diseases 24, 297-301. Ikegami, T., Narayanan, K., Won, S., Kamitani, W., Peters, C. J. & Makino, S. (2009a). Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS pathogens 5, e1000287. Ikegami, T., Narayanan, K., Won, S., Kamitani, W., Peters, C. J. & Makino, S. (2009b). Dual functions of Rift Valley fever virus NSs protein: inhibition of host mRNA transcription and post-transcriptional downregulation of protein kinase PKR. Annals of the New York Academy of Sciences 1171 Suppl 1, E75-85.
485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535
Kakach, L. T., Wasmoen, T. L. & Collett, M. S. (1988). Rift Valley fever virus M segment: use of recombinant vaccinia viruses to study Phlebovirus gene expression. Journal of virology 62, 826-833. Keegan, K. & Collett, M. S. (1986). Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus. Journal of virology 58, 263-270. Kortekaas, J., de Boer, S. M., Kant, J., Vloet, R. P., Antonis, A. F. & Moormann, R. J. (2010). Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 28, 4394-4401. Kortekaas, J., Oreshkova, N., Cobos-Jimenez, V., Vloet, R. P., Potgieter, C. A. & Moormann, R. J. (2011). Creation of a nonspreading Rift Valley fever virus. Journal of virology 85, 12622-12630. Kortekaas, J., Antonis, A. F., Kant, J., Vloet, R. P., Vogel, A., Oreshkova, N., de Boer, S. M., Bosch, B. J. & Moormann, R. J. (2012). Efficacy of three candidate Rift Valley fever vaccines in sheep. Vaccine 30, 3423-3429. Langmead, B. & Salzberg, S. L. (2012). Fast gapped-read alignment with Bowtie 2. Nat Methods 9, 357-U354. Malykhina, O., Yednak, M. A., Collins, P. L., Olivo, P. D. & Peeples, M. E. (2011). A respiratory syncytial virus replicon that is noncytotoxic and capable of longterm foreign gene expression. Journal of virology 85, 4792-4801. McGinnes, L. W., Gravel, K. & Morrison, T. G. (2002). Newcastle disease virus HN protein alters the conformation of the F protein at cell surfaces. Journal of virology 76, 12622-12633. Milne, I., Stephen, G., Bayer, M., Cock, P. J. A., Pritchard, L., Cardle, L., Shaw, P. D. & Marshall, D. (2013). Using Tablet for visual exploration of secondgeneration sequencing data. Briefings in bioinformatics 14, 193-202. Muller, R., Saluzzo, J. F., Lopez, N., Dreier, T., Turell, M., Smith, J. & Bouloy, M. (1995). Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. The American journal of tropical medicine and hygiene 53, 405-411. Oreshkova, N., van Keulen, L., Kant, J., Moormann, R. J. & Kortekaas, J. (2013). A single vaccination with an improved nonspreading rift valley Fever virus vaccine provides sterile immunity in lambs. PloS one 8, e77461. Oreshkova, N., Cornelissen, L. A., de Haan, C. A., Moormann, R. J. & Kortekaas, J. (2014). Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen. Vaccine. Peeters, B. P., de Leeuw, O. S., Koch, G. & Gielkens, A. L. (1999). Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. Journal of virology 73, 50015009. Peeters, B. P., Gruijthuijsen, Y. K., de Leeuw, O. S. & Gielkens, A. L. (2000). Genome replication of Newcastle disease virus: involvement of the rule-of-six. Archives of virology 145, 1829-1845. Porotto, M., Salah, Z. W., Gui, L., DeVito, I., Jurgens, E. M., Lu, H., Yokoyama, C. C., Palermo, L. M., Lee, K. K. & other authors (2012). Regulation of paramyxovirus fusion activation: the hemagglutinin-neuraminidase protein stabilizes the fusion protein in a pretriggered state. Journal of virology 86, 1283812848. Romer-Oberdorfer, A., Mundt, E., Mebatsion, T., Buchholz, U. J. & Mettenleiter, T. C. (1999). Generation of recombinant lentogenic Newcastle disease virus from cDNA. The Journal of general virology 80 ( Pt 11), 2987-2995.
536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553
Sergel, T. A., McGinnes, L. W. & Morrison, T. G. (2000). A single amino acid change in the Newcastle disease virus fusion protein alters the requirement for HN protein in fusion. Journal of virology 74, 5101-5107. Terasaki, K., Won, S. & Makino, S. (2013). The C-terminal region of Rift Valley fever virus NSm protein targets the protein to the mitochondrial outer membrane and exerts antiapoptotic function. Journal of virology 87, 676-682. Weingartl, H. M., Zhang, S., Marszal, P., McGreevy, A., Burton, L. & Wilson, W. C. (2014). Rift Valley Fever Virus Incorporates the 78 kDa Glycoprotein into Virions Matured in Mosquito C6/36 Cells. PloS one 9, e87385. Won, S., Ikegami, T., Peters, C. J. & Makino, S. (2007). NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. Journal of virology 81, 1333513345. Yoshizaki, M., Hironaka, T., Iwasaki, H., Ban, H., Tokusumi, Y., Iida, A., Nagai, Y., Hasegawa, M. & Inoue, M. (2006). Naked Sendai virus vector lacking all of the envelope-related genes: reduced cytopathogenicity and immunogenicity. The journal of gene medicine 8, 1151-1159.
554 Table 1. Genetic changes in NSRNDV detected by next‐generation sequencing Segment SNP Frequency Region RVFV‐SeGFP T10C 50% C11A 100% A1604T 100% RVFV‐L G1181A 100% A1602C 100% T6325C 100% NDV‐GnGc‐∆F A4085C 100% A6951C 90% A8367G 95% T14476C 90% Passage 7 culture supernatant is used as RNA template (Fig. 2). SNPs present in ≥ 50% of sequence reads are shown * Counted from the 4th methionine of the M‐segment UTR = untranslated region, Pol. = polymerase
3'UTR 3'UTR 5'UTR Pol. gene Pol. gene 5'UTR Gn gene M gene HN gene L gene
AA change ‐ ‐ ‐ G388E ‐ ‐ Y303S* K155T I192M ‐
555 556 557
Figure legends
558 559
Figure 1. Transfection and infection-mediated NSR production. BHK-Rep2 cells
560
stably maintaining RVFV L and SeGFP genome segments were transfected with pCAGGS-
561
M or infected with NDV-GnGc at an MOI of 0.5. One day post transfection or infection,
562
supernatants were collected and titrated on BHK-21 cells to determine the level of NSR
563
progeny. TCID50 values were determined two days post infection by evaluation of eGFP
564
expression. Bars represent means and standard errors of three experiments.
565 566
Figure 2. Construction of NDV-GnGc-∆F and an F complementing cell line. A)
567
Schematic presentation of the NDV-GnGc and NDV-GnGc-∆F genome. B) QM5 cells
568
infected with NDV-GnGc and NDV-GnGc-∆F were stained for F, Gn and Gc expression
569
using IPMA one day post infection. C) IPMA of QM5 and QM5-FHerts cells using an α F-
570
monoclonal antibody. D) Confirmation of F deletion in NDV-GnGc-∆F genomic RNA
571
isolated from virus grown on QM5-FHerts cells and determined by conventional RT-PCR
572
using primers 5 and 6 (Table S1). E) DAPI staining of QM5 and QM5-FHerts cells infected
573
with NDV-GnGc-∆F one day post infection. Foci of syncytia forming cells are magnified.
574
F) Production of NSR progeny after infection of BHK-Rep2 cells at different MOIs with
575
NDV-GnGc or NDV-GnGc-∆F. One day post infection, supernatants were collected and
576
titrated on BHK-21 cells. TCID50 values were determined two days post infection by
577
evaluation of eGFP expression.
578 579
Figure 3. Adaptation of NDV-GnGc-∆F to BHK-Rep2 cells. A) BHK-Rep2 cells
580
stably maintaining RVFV L and SeGFP genome segments were infected with NDV-GnGc-
581
∆F at an MOI of 0.5. After reaching confluence, the cells were passaged to new plates
582
until, due to the presence of CPE, no cell passage was possible anymore. Starting from
583
passage 3, supernatants were passaged to fresh BHK-21 cells instead of sub-culturing
584
the BHK-Rep2 cells. NSR progeny and infectious NDV-GnGc-∆F present in the
585
supernatants was determined for each passage. The three pictures (eGFP expression,
586
phase contrast and Gn IPMA) represent the observed phenotype of BHK cells infected
587
with NSRNDV.
588 589
Figure 4. Construction and evaluation of NDV-GnGc-∆F site-directed mutant
590
mediated NSR production. A) Schematic presentation of the genomes of NDV-GnGc-
591
∆F, NDV-Gn*Gc-∆F, NDV-GnGc-∆F-HN* and NDV-Gn*Gc-∆F-HN*. B) Growth curve of
592
the site-directed mutants in QM5-FHerts cells. C) DAPI staining of QM5 and QM5-FHerts
593
cells and IPMA of BSR cells infected with the site-directed mutants. The mutants grown
594
on BSR cells were also evaluated for the presence of infectious progeny by testing
595
supernatants of infected BSR cells on fresh BSR cells. D) Confirmation of F deletion in
596
the NDV-GnGc-∆F site directed mutants genomic RNA isolated from virus grown on
597
QM5-FHerts cells and determined by conventional RT-PCR using primers 5 and 6 (Table
598
S1). E) Site-directed mutant-mediated NSR production. BHK-Rep2 cells were infected
599
with the site-directed mutants and 2 days post infection the level of NSR progeny was
600
determined in the supernatant (P0, first bar). The supernatant of P0 was subsequently
601
passaged to fresh BHK-21 cells. These cells were washed twice at 6 h post infection, and
602
at 4 days post infection the level of NSR progeny was determined (P1, second bar). Bars
603
represent means and standard errors of three experiments. F) Stability of NDV-Gn*Gc-
604
∆F-HN*-mediated NSR production. BSR cells were infected with NDV-Gn*Gc-∆F-HN*
605
and NSR and each 2-3 days post infection supernatants were passaged to fresh cells.
606
Levels of progeny NSR and NDV-Gn*Gc-∆F-HN* were determined after each passage by
607
titration using eGFP as a readout for NSR and CPE as a readout for NDV-Gn*Gc-∆F-
608
HN*. At the passages indicated with an asterisk (*) an additional cell passage was
609
performed.
610 611
Figure 5. Neutralization of NDV-GnGc, NDV-GnGc-∆F and NDV-Gn*Gc-∆F-HN*.
612
NDV-GnGc, NDV-GnGc-∆F and NDV-Gn*Gc-∆F-HN* were incubated with serial
613
dilutions of normal sheep serum or a sheep serum containing α-RVFV antibodies. After
614
1.5 h the virus-serum mixture was added to BHK-21 cells. Two days later cells were
615
fixed and evaluated for Gn expression using IPMA. Pictures (A) were taken from wells
616
containing the 1:40 serum dilutions and (B) neutralization titers are expressed as the
617
serum dilution able to block over 50% of infectious particles. The detection limit was a
618
serum dilution of 1:20.
619 620
Figure 6. Vaccination challenge experiment NSRNDV in mice. A) Survival curve of
621
mice vaccinated with either NSR, NSRNDV or NDV-GnGc-∆F (NDV). Three weeks post
622
vaccination mice were challenged with a lethal RVFV challenge dose. B) RVFV-specific
623
virus neutralization titers present in sera the day before challenge. C,D) RVFV
624
dissemination into the livers (C) and brains (D) of challenged mice determined by qRT-
625
PCR.
626 627
Figure 7. Model showing replication and processing of wild-type NDV (LaSota),
628
wild-type RVFV, NDV-GnGc-∆F and NDV-Gn*Gc-∆F-HN* virions. NDV enters
629
cells via fusion with the plasma membrane and progeny is formed by budding at the
630
plasma membrane. Due to the absence of trypsin like proteases the F protein is not
631
cleaved and progeny is not infectious. RVFV enters cells via the endosomal route and
632
buds from the trans-Golgi compartments. Resulting progeny is infectious. NDV-Gn*Gc-
633
∆F, previously grown on F complementing cells, enters cells via fusion with the plasma
634
membrane. Progeny virus is not infectious due to the absence of the F protein. Unknown
635
amounts of GnGc heterodimers are expected to be present in the viral envelope. NDV-
636
Gn*Gc-∆F-HN* virions follow the RVFV specific entry route, via endosomes, where after
637
infectious progeny is formed at the plasma membrane due to the presence of mutations
638
in HN and Gn.
639